FDG PET/CT in oncology: "raising the bar"

Area of Science:

• Nuclear Medicine
• Radiology
• Oncology

Background:

• Integrated positron-emission tomography/computed tomography (PET/CT) with 2-[(18)F]-fluoro-2-deoxy-D-glucose (FDG) has become a cornerstone in oncological imaging.
• Significant advancements in PET/CT scanner technology have occurred but are not fully utilized in clinical practice.

Purpose of the Study:

• To review technological developments in PET/CT imaging.
• To explore how refined imaging protocols can improve PET/CT accuracy and efficacy in oncology.
• To discuss emerging applications and future directions of FDG PET/CT.

Main Methods:

• Review of technological advancements in PET/CT scanners.
• Analysis of imaging protocol refinements for enhanced accuracy.
• Exploration of novel applications in radiotherapy planning and response assessment.

Main Results:

• FDG PET/CT has a well-established role in various tumor types.
• Technological progress offers potential for improved clinical outcomes.
• Emerging applications show promise for enhanced oncological care.

Conclusions:

• Further exploitation of advanced PET/CT technology and optimized protocols can significantly improve oncological imaging.
• Future developments include integrated PET/MRI and advanced data analysis for broader clinical impact.